Please login to the form below

Not currently logged in
Email:
Password:

defibrotide

This page shows the latest defibrotide news and features for those working in and with pharma, biotech and healthcare.

bluebird bio presents new data for beti-cel in beta thalassemia at EHA2021

bluebird bio presents new data for beti-cel in beta thalassemia at EHA2021

The biotech company added that grade 3 veno-occlusive liver disease observed in three study patients was attributed to busulfan conditioning and resolved with defibrotide treatment.

Latest news

  • Jazz Pharma bags FDA approval for rare disease drug Jazz Pharma bags FDA approval for rare disease drug

    The US regulator has approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) as a complication of a haematological stem cell transplant (HSCT).

  • SMC: Celgene's Abraxane 'too expensive' for Scotland SMC: Celgene's Abraxane 'too expensive' for Scotland

    Drugs that received positive opinions included Janssen's Invokana (canagliflozin) for type 2 diabetes, Jazz Pharmaceuticals' Defitelio (defibrotide) for liver disease, GSK's respiratory combination Relvar Ellipta (fluticasone furoate / vilanterol)

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    The $57 per share deal gives Jazz an immediate boost in its ex-US business as well as access to Gentium's Defitelio (defibrotide) drug for the treatment of severe hepatic

  • Gentium expects EMA rejection for defibrotide Gentium expects EMA rejection for defibrotide

    Gentium is expecting the European Medicines Agency (EMA) to turn down its investigational medicine defibrotide for a liver condition associated with stem cell transplantation. ... Dr Khalid Islam, president and CEO of Gentium, said the company was

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic veno-occlusive disease (approved EU/ NDA US)    . 250. ArmaGen/ Shire   . Licence, collaboration   . AGT-182, enzyme replacement therapy for Hunter

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...